ABSTRACT
Background: 1.Effect of atropinization with different methods.2.Outcomes in terms of duration of hospital stay and patients recovery. Methodology: An open-label randomized clinical trial was conducted in, Shri B M Patil Medical College Hospital and Reasearchcentre, Vijyapura, Karnataka in 108 individuals with OPC poisoning .We compared two groups that used a titrated dosing protocol based on a structured monitoring sheet for atropineinfusion with another group using an ‘ad hoc’ regime. The aim was to compare the efficacy andsafety of conventional bolus doses with individualized incremental doses of atropine for atropinization followed by continuous atropine infusion for management of OPC poisoning. Results: Out of 108 patients ,54 patients received conventional bolus dose atropine (group A) and 54 patient received rapidly incremental doses of atropine followed by infusion (group B).36 subjects analysed in group A and 32 in group B for moderate to severe poisoning.The mortality in group A was 11.1%(4/36) and in group B was 6.3%(2/32).The mean duration of atropinization in group A was 5.8hrs (348)in minutes compared to time 26.9minutes for group B. Conclusion: Administration of atropine using a fixed algorithm is easy and effective in providing the atropine requirement in management of early phase of acute OPC poisoning.Rapid incremental dose atropinization followed by atropine infusion reduces mortality and morbidity from OPC poisoning and shortens the length of hospital stay and early recovery .Incremental atropine and infusion should become the treatment of choice for OPC poisoning.
ABSTRACT
Background: Aim: To estimate microalbuminuria in non-diabetic patients with Acute Coronary Syndrome And assess the relationship between the two. Methodology: All patients age >18yrs, both sexes diagnosed as acute coronary syndrome based on history and relevant investigations and admitted in BLDEU’S Shri B.M PATIL Medical college hospital and research centre Vijayapur. microalbuminuria was measured at admission and compared with standard normal mean value. Results: This study was conducted on 60 patients, of the study group 70.0% were male and30.0% were female. The age ranged from 30 to 85 years of age. The mean age of thegroup was 55.5 ±13.19 SD. The known risk factors of ACS were studied and correlated,37.2 % of all patients were smokers, 31% were tobacco chewers, 24.7 % had diabetesmellitus, 31.8% were hypertensive and 8 % had family history of ACS. The meanmicroalbuminuria value in mg/dl for STEMI was 35 ± 0.30 SD, for NSTEMI it was 21±1.6 and for unstable angina it was 22 ± 1.0 SD. The mean microalbuminuria in patientswith ACS was 44.6 ± 3.2 SD mg/dl incompared to microalbuminuria levels of 30mg/l innormal population (p<0.0001). Conclusion:This study showed an correlation of microalbuminuria with ACS. This reinforcesthe fact that microalbuminuria acts as emerging potential risk factor marker.